Intravitreal Injections and Face Masks : Endophthalmitis Risk Before and During the COVID-19 Pandemic
Copyright © 2023 Karimi et al..
Purpose: To assess the added risk of acute endophthalmitis after intravitreal injections associated with the widespread use of face masks during the COVID-19 pandemic.
Methods: In this retrospective, single-center study, records of patients with acute endophthalmitis following intravitreal bevacizumab (IVB) injections during the pre-COVID era-that is, March 1st, 2013 to October 31st, 2019 -and the COVID-19 era-that is, March 1st, 2020 to April 1st, 2021 -were reviewed and compared.
Results: A total of 28,085 IVB injections were performed during the pre-COVID era; nine eyes of nine patients developed acute post-IVB endophthalmitis in this era, giving an overall incidence of 0.032% (3.2 in 10,000 injections). In the COVID era, 10,717 IVB injections were performed; four eyes of four patients developed acute post-IVB endophthalmitis in this era, giving an overall incidence of 0.037% (3.7 in 10,000 injections). The incidences of post-IVB endophthalmitis during these two eras were not statistically significantly different (P = 0.779).
Conclusion: Face masking protocols seem unlikely to impose any additional risk of post-IVB endophthalmitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of ophthalmic & vision research - 18(2023), 3 vom: 22. Juli, Seite 283-288 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Karimi, Saeed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 23.08.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18502/jovr.v18i3.13776 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360996175 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360996175 | ||
| 003 | DE-627 | ||
| 005 | 20231226084217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18502/jovr.v18i3.13776 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM360996175 | ||
| 035 | |a (NLM)37600920 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karimi, Saeed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intravitreal Injections and Face Masks |b Endophthalmitis Risk Before and During the COVID-19 Pandemic |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.08.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Karimi et al. | ||
| 520 | |a Purpose: To assess the added risk of acute endophthalmitis after intravitreal injections associated with the widespread use of face masks during the COVID-19 pandemic | ||
| 520 | |a Methods: In this retrospective, single-center study, records of patients with acute endophthalmitis following intravitreal bevacizumab (IVB) injections during the pre-COVID era-that is, March 1st, 2013 to October 31st, 2019 -and the COVID-19 era-that is, March 1st, 2020 to April 1st, 2021 -were reviewed and compared | ||
| 520 | |a Results: A total of 28,085 IVB injections were performed during the pre-COVID era; nine eyes of nine patients developed acute post-IVB endophthalmitis in this era, giving an overall incidence of 0.032% (3.2 in 10,000 injections). In the COVID era, 10,717 IVB injections were performed; four eyes of four patients developed acute post-IVB endophthalmitis in this era, giving an overall incidence of 0.037% (3.7 in 10,000 injections). The incidences of post-IVB endophthalmitis during these two eras were not statistically significantly different (P = 0.779) | ||
| 520 | |a Conclusion: Face masking protocols seem unlikely to impose any additional risk of post-IVB endophthalmitis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Endophthalmitis | |
| 650 | 4 | |a Face Mask | |
| 650 | 4 | |a Infection | |
| 650 | 4 | |a Intravitreal Injection | |
| 650 | 4 | |a COVID-19 | |
| 700 | 1 | |a Nikkhah, Homayoun |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadzadeh, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Ramezani, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Ansari, Iman |e verfasserin |4 aut | |
| 700 | 1 | |a Nouri, Hosein |e verfasserin |4 aut | |
| 700 | 1 | |a Abtahi, Seyed-Hossein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of ophthalmic & vision research |d 2008 |g 18(2023), 3 vom: 22. Juli, Seite 283-288 |w (DE-627)NLM216554829 |x 2008-2010 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:3 |g day:22 |g month:07 |g pages:283-288 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18502/jovr.v18i3.13776 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 3 |b 22 |c 07 |h 283-288 | ||